EXTRAADRENAL EFFECTS OF METYRAPONE INCLUDE INHIBITION OF THE 11-OXOREDUCTASE ACTIVITY OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE - A MODEL FOR 11-HSD-I DEFICIENCY
被引:40
作者:
RAVEN, PW
论文数: 0引用数: 0
h-index: 0
机构:
UNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLANDUNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND
RAVEN, PW
[1
]
CHECKLEY, SA
论文数: 0引用数: 0
h-index: 0
机构:
UNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLANDUNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND
CHECKLEY, SA
[1
]
TAYLOR, NF
论文数: 0引用数: 0
h-index: 0
机构:
UNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLANDUNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND
TAYLOR, NF
[1
]
机构:
[1] UNIV LONDON KINGS COLL HOSP,DEPT CLIN BIOCHEM,LONDON SE5 9PJ,ENGLAND
BACKGROUND AND OBJECTIVE Previous studies suggesting effects of metyrapone on extra-adrenal corticosteroid metabolism have involved significant alterations in plasma cortisol. We have therefore studied effects of metyrapone on urinary excretion of steroids in a group of patients treated concurrently with hydrocortisone so that changes in plasma cortisol were minimized. DESIGN Replacement doses of hydrocortisone (30 mg/day) were given concurrently with metyrapone (2-4 g/day) for 2 weeks. Blood samples were taken and 24-hour urinary steroid collections were made at baseline and after 1 and 2 weeks of treatment. PATIENTS Subjects were 6 female patients with major depression from a trial of metyrapone as an antidepressant. MEASUREMENTS Urinary steroid profiles were measured by gas chromatography; plasma cortisol and urinary free cortisol were measured by fluorescence immunoassay. RESULTS Plasma cortisol levels were not significantly decreased by treatment, while excretion of 11-deoxycortisol metabolites increased eightfold after 2 weeks indicating that concurrent hydrocortisone administration had not suppressed the adrenal. Ratios reflecting 11 beta-hydroxy/11-oxo metabolites of cortisol were significantly decreased, consistent with inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase (11-HSD). Other changes included significant decreases in the rates of 5 alpha vs 5 beta and of 20 alpha vs 20 beta reduction of corticosteroids. CONCLUSIONS Metyrapone has multiple effects on extra-adrenal corticosteroid metabolism and is the only agent we know of which selectively inhibits 11-oxoreductase. Metyrapone thus provides a model for 11-HSD I deficiency and a tool for in-vitro studies of cortisol-cortisone interconversion. The results also suggest mechanisms whereby corticosteroid effects can be regulated separately from corticosteroid synthesis.